Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
AbstractStem cell gene therapy approaches for Human Immunodeficiency Virus (HIV) infection have been explored in clinical trials and several anti-HIV genes delivered by retroviral vectors were shown to block HIV replication. However, gammaretroviral and lentiviral based retroviral vectors have limitations for delivery of anti-HIV genes into hematopoietic stem cells (HSC). Foamy virus vectors have several advantages including efficient delivery of transgenes into HSC in large animal models, and a potentially safer integration profile. This review focuses on novel anti-HIV transgenes and the potential of foamy virus vectors for HSC gene therapy of HIV. View Full-Text
Share & Cite This Article
Nalla, A.K.; Trobridge, G.D. Prospects for Foamy Viral Vector Anti-HIV Gene Therapy. Biomedicines 2016, 4, 8.
Nalla AK, Trobridge GD. Prospects for Foamy Viral Vector Anti-HIV Gene Therapy. Biomedicines. 2016; 4(2):8.Chicago/Turabian Style
Nalla, Arun K.; Trobridge, Grant D. 2016. "Prospects for Foamy Viral Vector Anti-HIV Gene Therapy." Biomedicines 4, no. 2: 8.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.